Tetracycline compounds with c8 polysaccharide modification and biosynthetic method and application thereof
By introducing polysaccharide modification at the C8 position of tetracycline compounds and synthesizing new compounds using recombinant strain technology, the problem of resistance to drug-resistant bacteria in existing tetracycline antibiotics has been solved. Significant inhibitory activity against Staphylococcus aureus and Enterococcus faecalis has been achieved, providing a new method for structural modification and biosynthesis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- INST OF MICROBIOLOGY CHINESE ACAD OF SCI
- Filing Date
- 2026-03-26
- Publication Date
- 2026-07-17
AI Technical Summary
Existing tetracycline antibiotics have limitations in structural modification, making them difficult to effectively combat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis, and there is a lack of new biosynthetic methods.
By introducing polysaccharide modification at the C8 position of tetracycline compounds, the ech gene cluster of *Streptomyces oryzae* was expressed in *Streptomyces micranthum* using recombinant strain technology, and new tetracycline compounds with C8 polysaccharide modification were synthesized. The compounds were then purified using resin adsorption and chromatography techniques.
The synthesized tetracycline compounds modified with C8 polysaccharide groups showed significant inhibitory activity against drug-resistant bacteria such as Staphylococcus aureus and Enterococcus faecalis, providing new structural modification groups and alternative compounds, and laying the foundation for the innovative development of tetracycline skeleton antibiotics.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3